Le sevrage tabagique des « fumeurs difficiles »

Perriot, J.; Underner, M.; Peiffer, G.; Houezec, Jacques Le; Samalin, Ludovic; Schmitt, Andrea; Chazeron, Ingrid de; Doly-Kuchcik, L.

doi:10.1016/j.rmr.2011.09.048

Cited by 24 publications

(6 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We think that the longer NRT in HCS may be explained by:weaning syndrome and/or craving are often intense; they are factors of smoking cessation failure in the short and medium term [9, 10]. …”

Section: Discussionmentioning

confidence: 99%

“…Hardcore smoking has become a major public health challenge for tobacco control and cancer prevention [1, 6–8]. So-called « Hard-core Smokers » (HCS) seem to be unaffected by prevention campaigns and tax increases on tobacco products: most of them have no intention, and never have had, to stop smoking because they love smoking and do not believe in its dangers [9–12]. Prevalence rates of hard core smoking are influenced by the criteria used to define the phenomenon and are affected by the lack of standard definition [13].…”

Section: Introductionmentioning

confidence: 99%

“…HCS smoke more than other smokers and therefore show more frequently comorbidities associated with smoking [14]. It therefore seems important to better understand the behaviour and profile of HCS to optimize the therapeutic strategy and the follow-up [9, 15]: HCS quickly begin to smoke regularly, have a greater level of consumption, and persist with their habit even though it makes them ill [10]. They frequently show higher levels of nicotine dependence [16–19].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Smoking cessation attempts: is it useful to treat hard core smokers?

Joly¹,

d’Athis²,

Gerbaud³

et al. 2016

Tob. Induced Dis.

Self Cite

View full text Add to dashboard Cite

BackgroundHard core smokers have been studied in many countries but only a few trials have compared the effectiveness of smoking cessation with other smokers. The objective of this study was to compare the frequencies of success in smoking cessation between hard-core smokers and other smokers.MethodsData were collected in Clermont-Ferrand from the Emile Roux dispensary ‘Pneumology and Tobaccology Centre’ between 1999 and 2009. Assistance with smoking cessation was proposed to 1367 patients but only 1296 patients were included: 219 HCS and 1077 other smokers. Smoking cessation was considered a success when patients were abstinent 6 months after the beginning of cessation. The profiles of the two types of smokers were compared using Chi square test and Student’s t test. Multivariate logistic regression was used to investigate the association between the smoking cessation result and the type of smokers.ResultsHCS more frequently consumed other psychoactive substances (41.1 % vs 25.7 % for other smokers; p < 0.001). Current depression was more frequent in HCS (46.6 % vs 34.8 % for other smokers; p = 0.001). Smoking cessation was less frequent in HCS (45.2 % vs 56.5 % for other smokers ; p = 0.002). In multivariate analysis, after controlling for other factors, the frequency of smoking cessation was not significantly associated with the type of smokers (p = 0.47). After limiting to initial factors (present before the beginning of smoking cessation), the frequency of smoking cessation was still not significantly associated with the type of smokers (p = 0.78).ConclusionSmoking cessation is possible for hard core smokers, who should be treated as other types of smokers taking into account other factors:the problem is how to encourage them to try to stop smoking.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Smoking cessation attempts: is it useful to treat hard core smokers?

Joly¹,

d’Athis²,

Gerbaud³

et al. 2016

Tob. Induced Dis.

Self Cite

View full text Add to dashboard Cite

show abstract

“…[1][2][3] Despite declining smoking prevalence in many countries, there are disparities among vulnerable patients, young people, and women. [4][5][6][7] Current treatment ranges from minimal counselling to pharmacological treatments and cognitive behavioral therapies (CBT). Validated pharmacotherapies include nicotine replacement therapy (NRT), varenicline, and bupropion.…”

Section: Introductionmentioning

confidence: 99%

“…Its consumption causes a complex dependence and has multiple harmful consequences, with various neoplastic, cardiovascular, and respiratory diseases, inflicting a high cost on society 1 – 3 . Despite declining smoking prevalence in many countries, there are disparities among vulnerable patients, young people, and women 4 – 7 …”

Section: Introductionmentioning

confidence: 99%

Insomnia and parasomnia induced by validated smoking cessation pharmacotherapies and electronic cigarettes: a network meta-analysis

Vanderkam,

Pomes,

Dzeraviashka

et al. 2024

CNS Spectr.

View full text Add to dashboard Cite

We aim to assess the relationship between validated smoking cessation pharmacotherapies and electronic cigarettes (e-cigarettes) and insomnia and parasomnia using a systematic review and a network meta-analysis. A systematic search was performed until August 2022 in the following databases: PUBMED, COCHRANE, CLINICALTRIAL. Randomized controlled studies against placebo or validated therapeutic smoking cessation methods and e-cigarettes in adult smokers without unstable or psychiatric comorbidity were included. The primary outcome was the presence of “insomnia” and “parasomnia.” A total of 1261 studies were selected. Thirty-seven studies were included in the quantitative analysis (34 for insomnia and 23 for parasomnia). The reported interventions were varenicline (23 studies), nicotine replacement therapy (NRT, 10 studies), bupropion (15 studies). No studies on e-cigarettes were included. Bayesian analyses found that insomnia and parasomnia are more frequent with smoking cessation therapies than placebo except for bupropion. Insomnia was less frequent with nicotine substitutes but more frequent with bupropion than the over pharmacotherapies. Parasomnia are less frequent with bupropion but more frequent with varenicline than the over pharmacotherapies. Validated smoking cessation pharmacotherapies can induce sleep disturbances with different degrees of frequency. Our network meta-analysis shows a more favorable profile of nicotine substitutes for insomnia and bupropion for parasomnia. It seems essential to systematize the assessment of sleep disturbances in the initiation of smoking cessation treatment. This could help professionals to personalize the choice of treatment according to sleep parameters of each patient. Considering co-addictions, broadening the populations studied and standardizing the measurement are additional avenues for future research.

show abstract